Heather McKenzie is a Senior Editor at BioSpace. With over five years of experience in the biopharmaceutical industry, she specializes in neuroscience and gene therapy while also covering a range of topics including oncology, psychedelic research, and pharmaceutical regulation. Her work has been featured in NewsBreak, ESG Investor, AM850 WRUF, and WUFT News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Heather's coverage is predominantly focused on the healthcare and pharmaceutical industry, with a specific emphasis on FDA approvals, gene therapy, CRISPR technology, drug development, Alzheimer's disease, and CNS diseases. Her articles heavily cite data and press releases.
Given Heather’s focus on citing data and press releases in her articles about healthcare and pharmaceuticals, she may be interested in receiving pitches from experts who can provide statistical analysis or insights based on solid scientific evidence related to these topics. Pitches offering access to exclusive data or early access to research findings could also be appealing.
Heather does not appear to have a specific geographic focus but rather seems to cover global developments within the healthcare and pharmaceutical industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
· · · · · · · · · · · · Subscribe to GenePool
Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychiatric diseases, with a “continuum of care” mindset.
By: Gabrielle-Masson, Heather-Mckenzie
Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking pancreatic cancer drug; BioNTech suspends a mid-stage trial of its mRNA cancer immunotherapy after a futility analysis; and nine mid-sized biopharma companies join their big pharma peers in President Donald Trump's Most Favored Nation drug pricing scheme.
Inspection access is not “an administrative footnote,” leaders of key FDA divisions wrote in an editorial on Wednesday vowing to expand oversight of foreign clinical trial sites.
By: Heather McKenzie
The data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall response rate and overall survival of 16 months.
By: Heather-Mckenzie
Zanvastro, an antisense oligonucleotide therapy, represents the first independent neurology launch for Ionis Pharmaceuticals, which intends to leverage the foothold for more approvals in rare neurodegenerative diseases, including Angelman syndrome.
Date: Thursday, September 10, 2026 8am–5:45pm PDT Event Location: San Francisco, California
By: Gabrielle-Masson, Heather-Mckenzie
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx's big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis' Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
By: Heather McKenzie
The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.
By: Heather McKenzie
A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and Merck revealed positive Phase 3 results for their personalized mRNA-based cancer vaccine. In the words…
